Get the Stockscreener App
7.17
2.28%
0.16
Xeris Biopharma Holdings Inc stock is traded at $7.17, with a volume of 1.53M.
It is up +2.28% in the last 24 hours and down -5.53% over the past month.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).
See More
Previous Close:
$7.01
Open:
$7.09
24h Volume:
1.53M
Relative Volume:
0.64
Market Cap:
$1.19B
Revenue:
$246.03M
Net Income/Loss:
$-32.00M
P/E Ratio:
-33.74
EPS:
-0.2125
Net Cash Flow:
$-16.78M
1W Performance:
+10.14%
1M Performance:
-5.53%
6M Performance:
+62.22%
1Y Performance:
+110.88%
1-Day Range:
$7.00
$7.20
1-Week Range:
$6.5664
$7.30
52-Week Range:
$3.14
$10.08
Xeris Biopharma Holdings Inc Stock (XERS) Company Profile
Name
Xeris Biopharma Holdings Inc
Sector
Industry
Phone
844-445-5704
Address
1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL
Compare XERS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XERS
Xeris Biopharma Holdings Inc
|
7.17 | 1.16B | 246.03M | -32.00M | -16.78M | -0.2125 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Xeris Biopharma Holdings Inc Stock (XERS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | Barclays | Overweight |
| Aug-12-25 | Resumed | H.C. Wainwright | Buy |
| Nov-11-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Mar-28-24 | Initiated | Oppenheimer | Outperform |
| Aug-28-23 | Initiated | Craig Hallum | Buy |
| Oct-21-22 | Initiated | Jefferies | Buy |
| Apr-28-22 | Initiated | Craig Hallum | Buy |
| Nov-17-21 | Initiated | SVB Leerink | Outperform |
| Oct-29-21 | Initiated | H.C. Wainwright | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Feb-18-20 | Initiated | Piper Sandler | Overweight |
| Jul-16-18 | Initiated | Jefferies | Buy |
| Jul-16-18 | Initiated | Leerink Partners | Outperform |
| Jul-16-18 | Initiated | RBC Capital Mkts | Outperform |
View All
Xeris Biopharma Holdings Inc Stock (XERS) Latest News
Walleye Capital LLC Sells 448,444 Shares of Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
Jump Financial LLC Raises Stock Position in Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
561,700 Shares in Xeris Biopharma Holdings, Inc. $XERS Bought by Norges Bank - MarketBeat
Xeris Biopharma (NASDAQ:XERS) Coverage Initiated at Barclays - MarketBeat
Barclays Initiates Coverage on Xeris Biopharma Holdings (XERS) w - GuruFocus
Xeris Biopharma (XERS): Valuation Check After USPTO Notice of Allowance for Weekly Levothyroxine XP-8121 Patent - Sahm
Xeris Biopharma’s (XERS) Positioning Strengthens After Reaching Product Pipeline Milestone - Insider Monkey
7 Hidden Multibagger Stocks to Invest In - Insider Monkey
Xeris Biopharma Holdings (XERS) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Xeris Biopharma (XERS) Is Down 9.3% After XP-8121 Patent Milestone Is Announced – Has The Bull Case Changed? - Yahoo Finance
Is Xeris Biopharma (XERS) Using XP-8121 Patents to Quietly Redefine Its Long-Term Growth Story? - Sahm
How Xeris Biopharma Holdings Inc. stock performs in weak economy2025 Price Momentum & Verified Trade Idea Suggestions - Newser
Why Xeris Biopharma Holdings Inc. (2B30) stock is favored by hedge funds2025 Momentum Check & Fast Gain Stock Tips - Newser
What Wall Street predicts for Xeris Biopharma Holdings Inc. stock price2025 Major Catalysts & Verified High Yield Trade Plans - Newser
How higher bond yields impact Xeris Biopharma Holdings Inc. (2B30) stockJuly 2025 Opening Moves & Community Verified Watchlist Alerts - Newser
Xeris Biopharma (NASDAQ:XERS) Insider Sells $116,835.67 in Stock - MarketBeat
Xeris Biopharma (NASDAQ:XERS) Shares Down 4.9%Here's Why - MarketBeat
What Analysts Think Is Changing The Story For Xeris Biopharma Holdings - Yahoo Finance
What is Xeris Biopharma Holdings Inc (XERS) Stock Return on Shareholders’ Capital? - Setenews
Risks Still Elevated At These Prices As Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Dive 35% - simplywall.st
Legal & General Group Plc Purchases 392,589 Shares of Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
Is Xeris Biopharma Holdings Inc. stock a safe buy before earningsEarnings Growth Summary & Safe Capital Growth Plans - Newser
Why Xeris Biopharma Holdings Inc. (2B30) stock appeals to dividend investorsMarket Risk Analysis & Growth Focused Entry Reports - Newser
Hecht Beth, Xeris Biopharma chief legal officer, sells $116k in XERS - Investing.com India
Hecht Beth, Xeris Biopharma chief legal officer, sells $116k in XERS By Investing.com - Investing.com South Africa
Xeris Biopharma Holdings Director Beth Hecht Sells Shares - TradingView
Officer Hecht Sells 16,667 ($116.8K) Of Xeris Biopharma Holdings Inc [XERS] - TradingView
Oversold Conditions For Xeris Biopharma Holdings (XERS) - Nasdaq
Why Xeris Biopharma Holdings Inc. (2B30) stock is listed among top recommendations2025 Institutional Moves & Daily Stock Momentum Reports - Newser
A Look at Xeris Biopharma (XERS) Valuation After Patent Progress on Novel Hypothyroidism Therapy - Sahm
Xeris Pharmaceuticals Secures Patent Allowance for XP-8121 - MSN
Xeris Biopharma receives patent allowance for hypothyroidism drug By Investing.com - Investing.com Australia
Is Xeris Biopharma Holdings Inc 2B30 a good long term investmentPrice Action Analysis & Small Investment Growth Tips - earlytimes.in
Xeris Biopharma Receives Notice of Allowance for XP-8121 Patent - marketscreener.com
Xeris BioPharma Holdings Incunit receives USPTO notice of allowance for XP-8121 patent - marketscreener.com
Xeris Biopharma (XERS) Advances with New Patent Approval - GuruFocus
Xeris Biopharma receives patent allowance for hypothyroidism drug - Investing.com
Xeris Biopharma Holdings, Inc. Receives Notice of Allowance for XP-8121 Patent - TradingView
Xeris Announces Notice of Allowance from U.S. Patent and Trademark Office for XP-8121 Patent Application - marketscreener.com
Xeris Biopharma (Nasdaq: XERS) receives USPTO Notice of Allowance for XP-8121 - Stock Titan
Prudential Financial Inc. Buys 457,784 Shares of Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
Intech Investment Management LLC Has $441,000 Position in Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
Geode Capital Management LLC Boosts Stock Position in Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
Adversity is less terrifying than hope: Xeris Biopharma Holdings Inc (XERS) - Setenews
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Xeris Biopharma Holdings, Inc. $XERS Shares Acquired by CenterBook Partners LP - MarketBeat
What drives Xeris Biopharma Holdings Inc 2B30 stock priceDividend Stability Analysis & Stay Safe With Built-In Risk Monitoring - earlytimes.in
Xeris Biopharma Faces Weak Start with 15% Gap Down Amid Market Concerns - Markets Mojo
Will Xeris Biopharma Holdings Inc. (2B30) stock hit Wall Street targetsPortfolio Value Summary & Low Drawdown Investment Ideas - newser.com
Xeris Biopharma Holdings (XERS) Price Target Increased by 27.78% to 11.73 - MSN
Will Xeris Biopharma Holdings Inc. stock deliver long term returns2025 Bull vs Bear & AI Powered Buy and Sell Recommendations - newser.com
Xeris Biopharma Holdings Inc Stock (XERS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Xeris Biopharma Holdings Inc Stock (XERS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hecht Beth | See Remarks |
Dec 01 '25 |
Sale |
7.01 |
16,667 |
116,781 |
1,320,176 |
| Shannon John Patrick Jr | See Remarks |
Nov 14 '25 |
Option Exercise |
1.55 |
87,100 |
135,005 |
2,730,253 |
| Shannon John Patrick Jr | See Remarks |
Nov 13 '25 |
Option Exercise |
1.55 |
8,970 |
13,904 |
2,666,395 |
| Shannon John Patrick Jr | See Remarks |
Nov 13 '25 |
Sale |
7.46 |
23,242 |
173,402 |
2,643,153 |
| Hecht Beth | See Remarks |
Nov 11 '25 |
Sale |
7.40 |
16,667 |
123,296 |
1,336,843 |
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):